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Abstract
Trypanosomal S-adenoyl-L-homocysteine hydrolase (Tc-SAHH), considered as a target for
treatment of Chagas disease, has the same catalytic mechanism as human SAHH (Hs-SAHH) and
both enzymes have very similar X-ray structures. Efforts toward the design of selective inhibitors
against Tc-SAHH targeting the substrate binding site have not to date shown any significant
promise. Systematic kinetic and thermodynamic studies on association and dissociation of
cofactor NAD/H for Tc-SAHH and Hs-SAHH provide a rationale for the design of anti-parasitic
drugs directed toward cofactor-binding sites. Analogues of NAD and their reduced forms show
significant selective inactivation of Tc-SAHH, confirming that this design approach is rational.
1. Introduction
Professor Morris J. Robins has made many meritorious contributions to the field of modified
nucleosides and we wish in this review to discuss work carried out under his intellectual
influence.
S-Adenosyl-L-homocysteine (AdoHcy) hydrolase (SAHH; EC 3.3.1.1.) is the only known
enzyme responsible for the reversible conversion of AdoHcy to adenosine (Ado) and
homocysteine (Hcy) (Scheme 1.1.). SAHH occurs downstream of the S-adenosylmethionine
(AdoMet)-dependent transmethylation enzymes,1, 2 which are involved in a wide variety of
important biological functions. The methyl acceptors in this pathway include
macromolecules such as proteins, nucleic acids, and polysaccharides, and small molecules
such as histamines and phospholipids3. AdoHcy is a powerful product inhibitor which
regulates the AdoMet-dependent methyl transfers, so that SAHH plays a crucial role in the
AdoMet-dependent transmethylation pathway through controlling the intracellular levels of
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AdoHcy1. The catabolic reaction of AdoHcy favors the hydrolytic direction under
physiological conditions1. Thus, inhibition of SAHH in mammalian cells will result in
increased cellular levels of AdoHcy and further blocking of the methyl cycle.
SAHH has been considered an antiviral target in chemotherapy for decades, the 5'-terminus
of viral mRNA being an AdoMet-dependent transmethylase substrate4, 5. Moreover, an
overactive malfunction of SAHH will result in abnormally high blood levels of Hcy, which
increases the risk of cardiovascular disease6–8 and possibly amyloid diseases9, and so SAHH
has been considered as a target for treatment of these diseases as well. Recently, a new
pharmacological interest has developed in inhibitors of SAHH as anti-parasitic agents10.
2. The importance of selective inhibitors against Tc-SAHH as therapeutics
in Chagas disease
Besides mammalian organisms, parasites such as Trypanosoma cruzi11, Plasmodium
falciparum12 and Leishmania donovani10, 13 also encode their own SAHHs (Tc-SAHH, Pf-
SAHH and Ld-SAHH, respectively) as well as AdoMet-dependent methyltransferases14. As
in mammalian organisms, parasitic AdoMet-dependent methyltransferases serve to
methylate the 5'-terminus of mRNAs, which is important for growth14. Thus, inactivation of
parasitic SAHHs will result in the blocking of methyl transfer and will suppress the growth
of parasites. Earlier studies10, 11 have shown that there are differences in some kinetic and
thermodynamic parameters between human and parasite enzymes. Parasite enzymes have
weaker binding affinities for NAD+ and/or lower catalytic activities than those of the human
enzyme10, 11. These differences provide the possibility of designing selective inhibitors of
parasite SAHHs that will not inhibit human SAHH (Hs-SAHH).
In this review we are specifically interested in Trypanosoma cruzi. There currently are 8–11
million people infected with Chagas disease (also known as American trypanosomiasis) by
the protozoan parasite Trypanosoma cruzi (Center for Disease Control and Prevention,
Chagas Disease Detailed Fact Sheet, March 2009). This disease is transmitted by triatomine
insects when they feed on the blood of human hosts15. Chagas disease mainly resides in
rural areas of Mexico, Central America and South America and seriously threatens the
public health there15. Because of increased population movement, it has been reported that
there are rare cases in southern parts of the USA (Center for Disease Control and
Prevention, Chagas Disease Detailed Fact Sheet, March 2009). A study of the distinguishing
structural and enzymological features between Hs-SAHH and Tc-SAHH could lead to
development of compounds with clinical potential as anti-parasitic agents and eventually to
improved treatments of Chagas disease.
3. Structural similarities between Hs-SAHH and Tc-SAHH
So far there are fifteen available X-ray structures of SAHH from different sources (Protein
Data Bank files: 1A7A, 1KY4, 1KY5, 1LI4, 1D4F, 1XWF, 1K0U, 2H5L, 1XBE, 1V8B,
2ZIZ, 2ZJ0, 2ZJ1, 3CE6, 3DHY) including wild-type enzymes from human placenta, rat
liver, Plasmodium falciparum, Trypanosoma cruzi (unpublished data), and Mycobacterium
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tuberculosis as well as various mutated forms. The alignment of SAHH amino acid
sequences from different sources shows the primary structure is highly conserved1.
3.1. The structure of Hs-SAHH
Hs-SAHH is a homotetramer (Figure 1) composed of four ~ 47.5 kDa monomers1, 16. Each
monomer has 432 residues and can be divided into three parts: one substrate-binding
domain, one cofactor-binding domain (complexed to a molecule of NAD+/NADH) and a
small C-terminal extension or “tail”1, 16. Both structure and normal mode analysis identify a
hinge region [residues 182–196 (hinge region 1) and 352–356 (hinge region 2)] which
connects the substrate-binding domain (SBD, residues 5–180 and 357–374) with the
cofactor-binding domain (CBD, residues 191–356)1, 17, 18. This hinge regulates a ~ 19°
reorientation of the SBD relative to the CBD in the direction of the open-to-closed transition
and enables a conformational change in SAHH, which plays an important role in substrate
capture and in the subsequent series of catalytic reactions16, 17.
Between the SBD and the CBD there is a deep cleft which works as a channel for substrates
entering the active site and also for products being released into solution1. In terms of
quaternary structure, the tetramer is composed of two dimers, formed by monomers A and
B, and monomers C and D, respectively. The two dimers bind each other tightly and build a
“dimer of dimers”1. The short tail (residues 380–432) of monomer A extends into monomer
B and helps to form the cofactor-binding site of monomer B, and vice versa1. This dual
interpenetration also occurs between monomers C and D1. Moreover, the four cofactor-
binding domains from the four monomers bind each other tightly to form a central core with
the four substrate-binding domains facing outside1.
The available X-ray structures show that there are two different conformations of SAHH:
the open form and the closed form. Since rat SAHH shares 97% sequence identity with the
human enzyme, the entire protein structure of rat SAHH is assumed to be very similar to that
of the human enzyme19. The open conformation comes from the structure of the rat enzyme
(PDB code: 1KY4)20 while the closed conformation is from the structure of the human
placental enzyme [PDB code: 1A7A1 or 1LI416]. It is worth emphasizing that the X-ray
structure (PDB:1A7A) of SAHH which contains the inhibitor DHCeA shows a twisted-
closed conformation: a 14° reorientation of two halves of the homotetramer seem to seal the
enzyme core1. Comparison of the open and closed conformations, Figure 2, shows a 19°
rotation of the substrate binding domain toward the cofactor binding domain, which leads
from the open to the closed conformation. The open-to-closed conformational transition is
related to the catalytic reactions involving the substrate and cofactor NAD(H) in the active
site. The open conformation of SAHH enables substrate binding and the closed
conformation provides a closer contact between substrate and cofactor in the active site, as is
needed for catalysis. The enzyme converts back to the open conformation upon product
release21.
Besides the X-ray structures, there is other evidence for SAHH domain motions.
Computationally, normal mode analysis of low-frequency collective motions of SAHH
reveals the different mechanical properties of the open and closed forms of SAHH. The
hinge-bending motion in the direction of the open-to-closed conformational transition is
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unique to the open form of SAHH and occurs independently of other protein vibrations17. In
the closed form, normal mode calculations show the amplitude of the hinge-bending motion
in each subunit of SAHH is smaller than that in the open form, and the hinge bending
motions of individual subunits are strongly coupled to each other and other low frequency
vibrations, including subunit reorientations17. This mechanical coupling, a characteristic of
the closed form, may transmit the information of any structural changes related to the
catalytic reactions in one of the four active sites to the other active sites. Normal mode
analysis also suggested that the 20-ps hinge-bending vibrations of subunits reach an
amplitude of motion of ~ 1° which is much smaller than the amplitude of 19° in the global
structural transition, so the 19° SBD vs. CBD reorientation cannot be described as a simple
elastic deformation17.
Experimentally, time-resolved fluorescence anisotropy measurements were carried out on
native SAHH and three catalytically active mutants, M351P, H353A and P354A, all labeled
with the fluorescent probe PMal at residues C113 and C42118. Data analysis was focused on
the time constants for reorientation motions. The data for wild type SAHH with/without
ligand provides important information on the effect of ligand binding and oxidation on
hinge-bending motions. Wild type SAHH without substrate exhibits three rotational
correlation times: a time constant of 0.5 ns reflecting local chromophore reorientations and
protein vibrations; one of 14 ns involving domain reorientation; and a third of 82 ns
manifesting the overall protein tumbling in solution18. Wild type SAHH bound with 3'-
deoxyAdo/NAD+ or 3'-keto-Ado/NADH (Ado/NAD+) shows a similar three-component
anisotropy decay, but for wild type SAHH bound with 3'-keto-NepA/NADH, the 10-20 ns
domain reorientation is not detected18. These results indicate that there is an equilibrium
between open and closed structures of SAHH. This equilibrium is shifted toward a more
mobile open form in the substrate-free enzyme (E-NAD+), as well as in complexes with
intermediates formed early in the catalytic cycle after substrate binding or formed late prior
to product release (E-NAD+/ligand). This equilibrium is shifted toward the more rigid closed
form in SAHH complexes of analogues of the central catalytic intermediate (E-NADH/
ligand)18. In addition, fluorescence anisotropy decay studies of three mutant enzymes with/
without ligand illuminated the roles of the mutated residues in the hinge region 2 (residues
352–356) in hinge bending motions. Mutants M351P and P354A show a similar pattern of
behavior to wild type SAHH, which indicates that residues M351 and P354 have no
significant effects on domain motion18. For the H353A mutant, the 10-20 ns domain motion
was not detected either with or without ligand, and the longest component was shortened to
55–71 ns for all four ligation states of mutant H353A. This indicates mutant H353A changes
its domain motion dynamics independent of the presence of ligand or oxidation state of
cofactor18. Since the H353A mutant remains catalytically active, this mutant may slow
down its hinge bending motions to a longer time scale similar to that of overall protein
tumbling or longer, or exhibit a modified shape of the protein18. If the hinge bending
motions slow down to the time scale of enzyme turnover (the order of a second), this would
be out of the detectable range for fluorescence anisotropy decay (0.1 – 200 ns)18. Overall,
hinge region 2 makes no direct contribution to catalytic activity. In contrast, hinge region 1
contains residues N181, K186, N190, N191 which are in the active site, which are involved
in binding the substrate and thus are directly able to affect the activity18.
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To get a direct and clear picture of the domain motions of SAHH, a 15 ns dynamics
simulation of the open form of SAHH with explicit solvent was performed using Amber7
software. Very similar to the X-ray structure, the trajectories show that at the tetramer level
the four cofactor binding domains form a central core which remains relatively rigid, and
that the four substrate binding domains, located at the protein exterior, exhibit flexible
reorientations of large amplitude. Interestingly, the fluctuations of domains between open
and closed conformations within each subunit constitute only ~ 20% of the trajectory
domain motions. At the tetramer level, the remaining ~ 80% of the domain motions are
perpendicular to the direction of the open-to-closed structural transition, and may be
described as a “breathing-type” motion with substrate-binding domains moving to and from
the tetrameric core of SAHH. Furthermore, the domain reorientations in solution can be
represented as a combination of a faster process with 20–50 ps rotational correlation times
and 3–4° amplitude, and a slower process with 8–23 ns correlation times and 14–22°
amplitude. The time scale of the faster process is very close to that of the hinge-bending
vibrations which were found in the normal mode analysis while the slow process well
matches the fluorescence anisotropy decay measurements, which detected the 10-20 ns
domain motion with ca. amplitude of 26° in SAHH without substrate. Therefore, the slow
process is assigned to the rotational diffusion of the domains within a cone with 10-20° half-
angle. Overall, the results of the simulation agree with the previous data and help us to better
understand SAHH domain motions in solution22.
3.2. The structure of Tc-SAHH
The SAHH of Trypanosoma cruzi (437 aa and ~ 48 kDa per subunit) was cloned and
purified in this laboratory11. The sequence of Tc-SAHH shares 74% identity with Hs-
SAHH11. The X-ray structure of Tc-SAHH treated with the inhibitor Neplanocin A has been
recently determined (unpublished data of Drs. Q.-S. Li and W. Huang). Comparison of the
X-ray structures of Hs-SAHH and Tc-SAHH shows that there is no significant difference
between them at the structural levels of the tetramer, subunit, CBD, SBD and C-terminal
extension. The residues directly interacting with the substrate and the residues directly
interacting with NAD+ are all conserved. However it was reported that parasitic enzymes
such as Tc-SAHH11, Ld-SAHH10 and Pf-SAHH (unpublished data, S. Cai) bound cofactor
NAD+ less tightly than Hs-SAHH, which suggests that there ought to be some structural or
dynamic factors causing the differences in properties between Hs-SAHH and parasite
enzymes.
4. The catalytic mechanism of SAHH
SAHH is a hydrolase for which the catalytic mechanism was the topic of intense earlier
studies. Briefly, the catalytic reaction of SAHH for human and parasite is the reversible
hydrolysis and synthesis of AdoHcy to/from Ado and Hcy.
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This equilibrium favors the hydrolytic direction in vivo because of rapid removal of products
- Ado catalyzed by Ado deaminase and Hcy by the transsulfuration pathway. In contrast,
thermodynamic equilibrium favors the synthetic direction in the biochemical assays in
vitro1.
The total catalytic process can be divided into two parts: a reduction/oxidization portion and
an elimination/addition part, which is shown as a cycle in Scheme 1.2.16, 23, 24. The redox
part utilizes a tightly bound NAD+/NADH as a cofactor for hydrogen transfer. In the
hydrolysis direction, the 3'-CH center of substrate AdoHcy transfers a hydride equivalent to
NAD+, forming 3'-keto-AdoHcy and NADH. In the 3'-keto-AdoHcy, the 4'-CH bond
susceptible to deprotonation and thus activates elimination of Hcy across the 4'–5' bond. The
elimination is followed by Michael addition of water to form 3'-keto-Ado. Tightly bound
NADH now returns a hydride equivalent to 3'-keto-Ado and the catalytic process is
completed with release of Ado from SAHH, which contains the cofactor again in the NAD+
state.
The catalytic cycle involves two enzyme conformational states (Protein Data Bank code:
1KY420 and 1A7A1, 21): an open-closed interconversion of each monomer, which regulates
substrate binding and product release, and a ~14° rotation of one dimer relative to the
second dimer, which leads to a reduction in the volume of the tetramer and may serve to
“seal” the closed form. The “sealed” active sites help to prevent contact with the
environment of intermediates among a series of transition states21, 25.
The kinetics of individual steps in the SAHH catalytic cycle have been measured and a
model suggested that integrates the kinetics, the structural and dynamic results, and the
findings from site-directed mutagenesis16. The model emphasizes the roles of avoidance of
abortive reactions and stabilization of transition states in achieving efficient levels of
catalysis16, 26–28. There are three 3'-keto intermediates in the catalytic cycle and none of
them could survive exposure to the aqueous buffer environment16.
Any release and/or exposure of intermediates will result in abortive products and an
uncompleted catalytic cycle. This is hindered by a tight closure of the active site, which
builds a barrier of 110 kJ/mol for abortive release of intermediates. This barrier is ~ 50
kJ/mol higher than a diffusional barrier and decreases the rate of abortive release by 108–109
fold16. In addition, the central intermediate 4', 5'-didehydro-5'-deoxy-3'-keto-adenosine also
needs to be protected from the nearby cofactor NADH to avoid premature reduction of the
3'-keto group of the intermediate16. The 3'-keto structure of the central intermediate is
crucial for activation of the next step of Michael addition of water/Hcy to the 4', 5'-double
bond. To achieve the necessary protection, residue His 301 shifts its position so that its side
chain buttresses the cofactor NADH at a greater separation from the intermediate. The result
is an apparent increase in distance of about 0.4 Å between C-4' of the cofactor NADH and
C-3' of the substrate16. The barrier for the abortive reduction of the central intermediate is
86–89 kJ/mol, which is 22–24 kJ/mol higher than the barrier for productive reduction (65–
67 kJ/mol). This difference in barrier heights results in a rate of productive reduction that is
faster by 103–104 fold than the rate of abortive reduction16. The catalysis of most steps in
the reaction depends on acid-base catalysis for transition-state stabilization, so that the
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potentially needed exchange of protons with the medium would seem to be difficult in the
closed conformation. However, SAHH appears to depend on a chain of water molecules to
deliver protons between the active site and the buffer environment to maintain the suitable
protonation states of functional residues during the catalytic cycle16.
Many attempts have been made to design mechanism-based inhibitors for Hs-SAHH
targeting the substrate binding site and utilizing its catalytic potentialities, and some
progress has been achieved1, 2, 29. The partial “oxidative” reaction (reduction/oxidation) and
partial “hydrolytic” (elimination/addition) reaction provide two design targets29. Type I
inactivators, which are oxidized to the 3'-keto form with SAHH catalysis and conversion of
NAD+ to NADH, target the oxidative partial reaction30. Neplanocin A (NepA) with a Ki of
8.4 nM is an example of type I inactivators and its catalytic reaction stops after oxidation at
the 3' position produces a material that is structurally an analogue of the central intermediate
4', 5'-didehydro-5'-deoxy-3'-keto-adenosine1, 31. On the other hand, type II inactivators are
not only oxidized in the 3'-position by SAHH but also form covalent bonds with enzyme
following reactions analogous to the elimination/addition partial reaction30. For example,
(E)-5', 6'-didehydro-6'-deoxy-6'fluorohomoadenosine (EDDFHA) is a type II inactivator by
generating electrophiles at the active site and forming a covalent bond to irreversibly
inactivate the enzyme32. Figure 3 shows the structures of the above two types of inhibitors
and their inactivation mechanisms.
5. Substrate binding site is not a suitable target for designing anti-parasitic
drugs
A good antiparasitic drug needs to show selective inhibition of parasitic SAHHs (such as
Tc-SAHH) without significant inactivation of Hs-SAHH. The available inhibitors against
Hs-SAHH such as NepA or DHceA are all substrate (Ado or AdoHcy) analogues. So the
substrate binding site was firstly considered as the target for designing anti-parasitic
selective inhibitors. But Type I and Type II inhibitors of Hs-SAHH are obviously unsuitable
as antiparasitic agents. Furthermore, Drs. Morris Robins and Stanislaw Wnuk kindly
provided a total of 122 substrate analogs (unpublished work) for a screen against both Hs-
SAHH and Tc-SAHH. There are only 12 compounds showing some weak selective
inhibition of Tc-SAHH while most of the remainder, 89 compounds, show no inhibition of
either enzyme. Only 10 compounds show roughly equivalent inhibition of both enzymes,
while 11 compounds show stronger inhibition of Hs-SAHH. In addition, ribavirin (1, 2, 4-
triazole-3-carboxamide riboside) was reported to show some time-dependent selective
inactivation of Tc-SAHH over Hs-SAHH38. But the KI values of ribavirin for Hs-SAHH
(266uM) and Tc-SAHH (194uM) are similar and the weak selectivity results from the
differential slow inactivation rate where ribavirin reacts with Tc-SAHH five times faster
than with Hs-SAHH.
Overall, we concluded that it was very unlikely that selective inhibitors targeted toward the
substrate binding site of Tc-SAHH would be identified.
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6. The cofactor binding site is a promising target for designing selective
inhibitors against Tc-SAHH
As mentioned in section 3.2, Tc-SAHH and other parasitic SAHHs show a weaker affinity
for the cofactor NAD+ than does Hs-SAHH. Such enzymological differences between Hs-
SAHH and parasitic SAHHs may provide a clue or rationale for designing selective
inhibitors against parasitic SAHHs. Therefore, the comparative kinetics of cofactor
association and dissociation for Hs-SAHH and Tc-SAHH have been studied
systemically33, 34.
6.1. The basic features of the cofactor association and dissociation process33
The equilibrium and kinetic properties of the association and dissociation of the cofactor
NAD+ from Hs-SAHH and Tc-SAHH form a very complex picture. In a word, those
properties of Hs-SAHH and Tc-SAHH are qualitatively similar but quantitatively distinct.
All data suggest that the four cofactor binding sites of the homotetrameric apoenzyme fall
into two numerically equal classes, one class denoted fast-binding sites and the other class
denoted slow-binding sites. Fast-binding sites possess a weak cofactor binding affinity but
occupation by cofactor generates enzymatic activity rapidly (< 1 min). Slow-binding sites
possess a relatively strong cofactor binding affinity but occupation by cofactor generates no
catalytic activity initially. Instead, it initiates a process in which the site is slowly (> 30
mins) transformed from a non-catalytic status to a catalytic-active status. This
transformation of the slow-binding site may involve a series of conformational changes
induced by cofactor binding, resulting in a delay of generation of catalytic activity. In
addition, the transformation of slow-binding sites must affect the fast-binding sites: the
cofactor binding affinity and catalytic activity of all four sites of the holoenzyme are same.
Thereafter, Tc-SAHH persistently exhibits a cofactor binding affinity at micromolar levels.
The slow-binding phase of Hs-SAHH terminates with a cofactor binding affinity also in the
micromolar range. Yet over a period of some 30 mins, Hs-SAHH develops a nanomolar
level of affinity for NAD+, due entirely to a decreased dissociation rate constant. The
structural reason for this increased cofactor affinity of Hs-SAHH is still unknown.
The kinetics of cofactor association with both human and trypanosomal apoenzymes create
saturation and exponential curves as a function of cofactor concentration. But the maximum
cofactor-binding rate constant of Hs-SAHH is ten times larger than that of Tc-SAHH.
Furthermore, the cofactor-association rate constant exhibits a complex temperature-
dependence such that NAD+ binds faster to Hs-SAHH than to Tc-SAHH above ~16 °C.
Compared to the cofactor-association process, the cofactor-dissociation process is relatively
simple. Cofactor NAD+ dissociates from all four binding sites in a single first-order reaction
for both Hs-SAHH and Tc-SAHH. However, cofactor always dissociates from Tc-SAHH
much more rapidly than from Hs-SAHH. For example, the cofactor-dissociation rate
constant of Tc-SAHH is 80-fold larger than that of Hs-SAHH at 37 °C. The differential
cofactor-dissociation rate constants provide a potential opportunity for inhibitors to bind
selectively to Tc-SAHH, which supports the idea that it is feasible to design selective
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inhibitors targeted toward the cofactor binding site and not toward the substrate-binding site,
as with previous efforts.
6.2. Structure elements responsible for differential cofactor binding properties (34 and
unpublished data)
Hs-SAHH and Tc-SAHH thus exhibit distinct kinetic and thermodynamic properties of
cofactor association and dissociation, which should be based on a structural distinction.
Although the X-ray structures show no significant differences between two enzymes, some
local elements near the cofactor-binding site may be important to NAD+ binding. The C-
terminal extension of SAHH is a flexible structure. The extension includes a short helix-18,
located 8 residues ahead of Lys, a final residue for Hs-SAHH and for three parasitic SAHHs
(Tc-SAHH, Ld-SAHH and Pf-SAHH). The residues Lys426 and Tyr430 in the C-terminal
loop of Hs-SAHH are found near NAD+ in X-ray structures, and may form hydrogen bonds
with NAD+. A stable helix-18 may help to locate residues Lys426 and Tyr430 at suitable
positions in the NAD+ binding pocket. Therefore, the relative stability of helix-18 should be
important for determining the differences in cofactor-association-dissociation and affinity
between human and parasitic enzymes. Each residue has its helix-propensity value, so the
helix-propensity value of helix-18 can be easily calculated according to its seven-residue
sequence. A high propensity value means a more stable helix structure. The hypothesis is
that the SAHH with a more stable helix-18 will bind the cofactor NAD+ more strongly. The
calculated helix-propensity values of helix-18 fall in a decreasing order Hs-SAHH (8.96) >
Tc-SAHH (8.35) > Ld-SAHH (7.73) > Pf-SAHH (7.31), consistent with the order of their
cofactor binding affinities as previously observed.
A mutagenesis approach was taken to create a “parasitized” human enzyme mutant, with
helix-18 of Hs-SAHH replaced by the less stable helix-18 of Pf-SAHH (Hs-18Pf-SAHH). A
“humanized” trypanosomal mutant was also constructed, with helix-18 of Tc-SAHH
replaced by the more stable helix-18 from Hs-SAHH (Tc-18Hs-SAHH). Both mutants
exhibit biphasic association kinetics (fast and slow binding) similar to that of wild type Hs-
SAHH and Tc-SAHH. The temperature dependence of the rate constant for NAD+
association shows a thermal transition for all SAHHs. The thermal-transition temperatures
follow the order Hs-SAHH (35 °C) > Hs-18Pf-SAHH (33 °C) > Tc-18Hs-SAHH (30 °C) >
Tc-SAHH (15 °C). These transitions are considered to arise from local structure changes
because the global unfolding temperatures of all four apo-SAHHs are greater than 40 °C.
The thermal-transition order for the four enzymes clearly indicates the influence of helix-18,
but doubtless reflects other properties of the “host enzyme” as well. The NAD+ dissociation
rate constants of all four enzymes also exhibit thermal transitions. The thermal-transition
temperatures decrease in the order Hs-SAHH (41 °C) > Hs-18Pf-SAHH (38 °C) > Tc-18Hs-
SAHH (36 °C) > Tc-SAHH (29 °C). This order matches the expected stability order for
helix-18. Here too it may reflect the contribution of other properties of the “host enzyme”.
Circular dichroism and differential scanning calorimetry provided the global unfolding
temperatures of all fully reconstituted holoenzymes which are around 63 °C and much
higher than the thermal-transition temperatures seen in the temperature dependence of the
NAD+ dissociation rate constants. This fact indicates that local structural alterations are the
origin of the thermal transitions.
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Besides the structure element helix-18 of the C-terminal extension, the β sheet of Rossmann
motif has also been identified as playing a role in NAD+ binding (unpublished data). The
Rossmann motif can be found in most classical NAD+ binding proteins35. Its βαβαβ unit
often associated with an additional β strand, forms a “core”, the minimum secondary
structure necessary for binding the cofactor36. In addition, the first 30–35 amino acids of the
“core” are a fingerprint region for the identification of dinucleotide binding. There are
several conserved characteristics within this fingerprint sequence: 1) a six-residue glycine-
rich sequence (GXGXXG) involved in phosphate binding; 2) six conserved positions
containing only hydrophobic amino acids; 3) a conserved, negatively charged residue and 4)
a conserved, positively charged residue35. Specifically, the six conserved hydrophobic
residues are located on the first β-sheet, the first α-helix and the second β-sheet, which form
a hydrophobic core and are crucial to pack the β-sheets against the α-helix in crucial
secondary-structure interactions36. Moreover, a second repeated βαβαβ unit, related to the
first one by a two-fold rotation, can usually be found in NAD(P)+ binding proteins36.
There are two classical Rossmann motifs seen in each subunit of SAHH: one in the
substrate-binding domain and the other in the cofactor-binding domain. The Rossmann
motif in the NAD+ binding domain has a second repeated βαβαβ unit. Alignment of the
fingerprint sequences (first 30–35 amino acids) of the Rossmann motif in the NAD+-binding
domain of human and parasitic SAHHs reveals that the two small conserved hydrophobic
residues on the first β-sheet of the Rossmann motif are conserved in Hs-SAHH and Pf-
SAHH, but replaced by two hydrophilic residues in Tc-SAHH and Ld-SAHH. The
replacement of the hydrophobic residues by two hydrophilic residues could weaken
hydrophobic interactions and increase the flexibility of the hydrophobic core formed by the
six hydrophobic residues and other residues. Such difference could influence NAD+
association, dissociation, and affinity.
The principle of our study of the first β sheet of the Rossmann motif is similar to that of our
study of the helix-18. The β-sheet propensity estimates of the first β sheet of the Rossmann
motif predict a greater stability of this sheet in Hs-SAHH than in parasitic SAHHs. The
enzymes with more stable β-sheets are expected to bind NAD+ more tightly. Parasitized Hs-
SAHH and humanized Tc-SAHH were created by mutations in the first β-sheet of the
Rossmann motif. Systematic kinetic and thermodynamic studies were performed on these
mutants. As expected, parasitized Hs-SAHH shows weaker cofactor binding affinity than
Hs-SAHH while humanized Tc-SAHH shows stronger cofactor binding affinity than Tc-
SAHH. The affinity changes indicate the role of this β-sheet in differential properties of the
human and parasitic enzymes.
These results confirm that structural distinctions between Hs-SAHH and Tc-SAHH cause
the observed differential kinetic properties and thermodynamic properties. Thus it seems a
promising avenue for anti-parasitic therapy to design inhibitors targeted on the cofactor
binding site of SAHH.
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6.3. Applications of NAD(/H) analogues as selective inhibitors of Hs-SAHH and Tc-SAHH
(See article by Li et al in this issue)
Analogues of NAD+ and its reduced form NADH can be divided into two categories: (a)
modifications in the nicotinamide part; (b) modifications in the adenine part. S-NAD and S-
NADH are the thione analogues of natural cofactors, modified in the nicotinamide part.
These two analogues have been reported to exhibit time-dependent inactivation of both Tc-
SAHH and Hs-SAHH but they show significant inactivation on Tc-SAHH during time
periods where they reduce the activity of Hs-SAHH very little. Under the competition of
natural cofactor NAD+ (50 μM) at 37 °C, S-NADH reaches an apparently complete
inactivation of Tc-SAHH within 20 mins. In contrast, S-NAD+ reaches and maintains an
apparent equilibrium of inactivation at 50% activity of Tc-SAHH. Under the same
conditions, Hs-SAHH loses only 10% of its activity in the presence of S-NAD or S-NADH
within 20 mins and reaches an apparent equilibrium inhibition only after twelve hours of
incubation.
So far seven analogues of NAD and their reduced forms have been tested on Tc-SAHH and
Hs-SAHH using the same approach (competition against 50 μM NAD+). H-NAD/H, C-
NAD/H, O-NAD are NAD/H analogues modified in the nicotinamide part. NGD, NHD/H
and ethno-NAD are NAD/H analogues modified in the adenine part. All structures are given
in Table 1. Investigations of these analogues of Hs-SAHH and Tc-SAHH were carried out at
37 °C in the presence of 50 μM NAD+ to simulate in vivo concentrations. None of these
analogues, either in oxidized form or reduced form, can inactivate Hs-SAHH by more than
4% within 6 mins. However, because cofactor NAD+ dissociates 90-fold faster from Tc-
SAHH than from Hs-SAHH, the analogues enjoy a greater probability of entrance to a
vacant cofactor binding site with Tc-SAHH, thus resulting in significant selective
inactivation. S-NADH and H-NADH are the best of the seven analogues, leading to more
than 90% inactivation of Tc-SAHH.
In summary, several analogues of NAD and NADH achieve selective inhibition under
conditions of competition with NAD+. NADH analogues are better candidates for selective
inhibition of Tc-SAHH because SAHH binds NADH more strongly than NAD+. Analogues
with modifications in the nicotinamide group do not exhibit cofactor function but, except for
O-NAD, they are strong competitive inhibitors. Analogues with modifications in the adenine
part show partial cofactor function, but are more weakly bound than NAD+ to Hs-SAHH by
four orders of magnitude. They are more weakly bound than NAD+ to Tc-SAHH by two
orders of magnitude. These observations suggest that the adenine group of NAD plays a
negligible role in cofactor function but makes a contribution to the cofactor-binding
interaction.
The successful in-vitro inhibition by NAD/H analogues of Tc-SAHH, but not Hs-SAHH,
support the design of selective inhibitors targeted on the cofactor binding site of SAHH.
Rational modifications of the structures of NAD and NADH may be capable of generating
candidate anti-parasitic drugs, especially for the treatment of Chagas disease.
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The role of SAHH in methyl transfer and metabolic pathways. Abbreviations: ADA,
adenosine deaminase; AK, adenosine kinase.
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Catalytic cycle of SAHH in both hydrolytic and synthetic directions with redox partial
reactions and elimination/addition partial reactions. B represents the enzymic residue that
accepts and returns the proton at the 4' position. SAHH with bound NAD+ exists in an open
conformation while SAHH with bound NADH exists in a closed conformation for a series of
catalytic reactions.
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The tetrameric structure of SAHH containing cofactor NAD+ (light ball-and-stick) (pdb
code: 1KY4). Four cofactor-binding domains (central dark regions) form the core at the
center and four substrate-binding domains (corners of the figure) are located outside.
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Open conformation (pdb: 1KY4, rat source) and closed conformation (pdb: 1LI4, human
source) of the SAHH monomer (created by Molecular Operation Environment). The top
domain is the cofactor-binding domain; the bottom domain is the substrate-binding domain;
the loop at the right is the C-terminal extension. SAHH in the open conformation contains
cofactor NAD+ (ball-and-stick) and SAHH in closed conformation contains cofactor NADH
(ball-and-stick) and oxidized inhibitor-NepA (ball-and-stick). From the open conformation,
the substrate-binding domain rotates ~ 19° toward to the cofactor binding domain to form an
active site for catalysis in the closed conformation.
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Type I inhibitor (NepA) and Type II inhibitor (EDDFHA) structure and their inactivation
mechanisms (adopted from Elrod, et al. 200237).
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Table 1





Thionicotinamide adenine dinucleotide (S-NAD)
right:
3-Pyridinealdehyde adenine dinucleotide (H-NAD)
left:
Nicotinic acid adenine dinucleotide (O-NAD)
right:
3-Acetylpyridine adenine dinucleotide (C-NAD)
left:
Nicotinamide hypoxanthine dinucleotide (NHD)
right:
Nicotinamide guanine dinucleotide (NGD)
Nicotinamide 1, N6-ethenoadenine dinucleotide (etheno-NAD)
a
Reproduced from the paper by Li et al. in this issue.
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